Avant Diagnostics Inc. | Balance Sheet

Fiscal year is October-September. All values USD Thousands.
2012
2013
2014
2015
2016
Cash & Short Term Investments
274.20
-
-
43.60
0.90
Total Accounts Receivable
-
-
-
-
41.40
Other Current Assets
21.60
-
-
0.00
-
Total Current Assets
295.80
-
-
43.70
42.20
Intangible Assets
-
-
-
1,795.10
5,613.80
Other Assets
-
-
-
-
20.00
Total Assets
295.80
-
-
1,838.70
5,676.00
ST Debt & Current Portion LT Debt
-
-
-
-
680.10
Accounts Payable
16.80
32.00
-
-
536.60
Other Current Liabilities
-
-
66.30
621.30
898.70
Total Current Liabilities
16.80
32.00
66.30
621.30
2,115.40
Total Liabilities
16.80
32.00
66.30
621.30
2,115.40
Common Equity (Total)
279.00
32.00
66.30
1,217.40
3,560.70
Total Shareholders' Equity
279.00
32.00
66.30
1,217.40
3,560.70
Total Equity
279.00
32.00
66.30
1,217.40
3,560.70
Liabilities & Shareholders' Equity
295.80
-
-
1,838.70
5,676.00

About Avant Diagnostics

View Profile
Address
1050 30th Street NW
Washington District of Columbia 20007
United States
Employees -
Website http://www.avantdiagnostics.com
Updated 09/14/2018
Avant Diagnostics, Inc. is a medical technology company, which engages in the research of human genome sequencing project. It also develops the OvaDx screening test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. The company is headquartered in Scottsdale, AZ.